Adaptive Biotechnologies (ADPT) Misses Q1 Revs; Withdraws Guidance

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q1 revenue for the quarter came in at $20.9 million versus the consensus estimate of $22.66 million.

GUIDANCE:

“Adaptive’s immune medicine platform was built to decode the specific immune response to any disease, which we are now applying in full force to COVID-19,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “Importantly, we are able to do this while maintaining focus on our current products and future pipeline.”

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• HP Inc. projects mid-single-digit PC market decline in 2027
• Standard Uranium extends private placement closing date to October 18
• RBC Capital Reiterates Sector Perform Rating on ExxonMobil (XOM)